B. Riley Securities analyst Jeff Van Sinderen downgrades Verso (NYSE:VRS) from Buy to Neutral and raises the price target from $18 to $20.
B. Riley Securities Downgrades Verso to Neutral, Raises Price Target to $20
B. Riley Securities analyst Jeff Van Sinderen downgrades Verso (NYSE:VRS) from Buy to Neutral and raises the price target from $18 to $20.
Related Posts
Barclays Maintains Overweight on Visa, Raises Price Target to $266
Barclays analyst Ramsey El-Assal maintains Visa (NYSE:V) with a Overweight and raises the price target from $264 to $266.
Trevi Therapeutics Q2 EPS $(0.49) Misses $(0.48) Estimate
Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 19.51 percent decrease over losses of $(0.41) per share
Telsey Advisory Group Maintains Market Perform on Nordstrom, Lowers Price Target to $19
Telsey Advisory Group analyst Dana Telsey maintains Nordstrom (NYSE:JWN) with a Market Perform and lowers the price target from $25 to $19.